Litcius/Paper detail

The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Danielle Peterson, William Damsky, Brett King

2020Journal of the American Academy of Dermatology31 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDermatologyContext (archaeology)Alopecia areataAtopic dermatitisClinical trialPandemicJanus kinasePsoriasisCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RuxolitinibImmunologyInternal medicineCytokineMyelofibrosisBone marrowBiologyPaleontologyInfectious disease (medical specialty)DiseasePsoriasis: Treatment and PathogenesisAutoimmune Bullous Skin DiseasesDermatology and Skin Diseases
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Litcius